Tag Archives: Study

Depression Drug Shows Promise for Future, Study Reports


Alpharetta, GA (PRWEB) November 25, 2014

The paper, “A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended Release In Patients with Major Depressive Disorder” was released in early 2014 and was the result of over one year of clinical research. Levomilnacipran, known as Fetzima ®, is a potent and selective serotonin and norepinephrine reuptake inhibitor that has been approved by the FDA for the treatment of depression. The research suggests that changes in symptom severity and improvement in functional impairment may occur asynchronously, with functional improvement often lagging behind symptoms. As such, symptom improvement may provide an early sign of treatment response, whereas functional improvement may be a better indicator of meaningful change according to a study published in the Journal of Clinical Psychopharmacology, Volume 34, Number 1, February 2014.

In this study conducted across a number of facilities that included Angelo Sambunaris, M.D., the research team performed trials to determine both efficacy (effectiveness) and tolerability (side effects) of the extended release (ER) formulation of this new medication.

“Studies like this one are an important step in the fight against depression,” said first author Dr. Sambunaris. Dr. Sambunaris is also the Founder and Medical Director of the Institute for Advanced Medical Research located in Alpharetta, GA. “We are always excited to share the results of our research studies with the medical community and patient group.”

About Angelo Sambunaris, M.D.

Dr. Angelo Sambunaris has been a leader in the field of clinical research for over two decades and currently serves as Founder, CEO and Medical Director of the Institute for Advanced Medical Research. He is also a clinical faculty member at the Mercer University School of Pharmacy. His experience helps him direct the clinical research team in conducting psychopharmacology (psychiatric medical care) and neuropharmacology (neurologic medical care) trials. The focus of his research is on Alzheimer’s disease and other dementias, anxiety disorders and depression, with additional interests in the areas of obsessive compulsive disorders, schizophrenia, stroke, insomnia, alcohol abuse/dependence, pain, migraine and obesity. As a veteran himself, he also has a particular interest in PTSD with soldiers.

Dr. Sambunaris earned his medical degree from the University of Colorado in Denver. Further studies continued with an internship in the Department of Medicine, Hershey Medical Center of the Pennsylvania State University; Psychiatry Residency, Department of Psychiatry, University of Colorado Health Sciences Center; Psychiatry Career Resident Program (externship), General Adult Psychiatric Services, Colorado State Hospital; and Clinical Staff Fellow, Neuropsychiatric Research Hospital National Institute of Mental Health, Washington, D.C.

In addition to his time in the Army and Colorado Army National Guard, he was also a member of the US Public Health Service and achieved the rank of Major with the Army and Lieutenant Commander in the PHS.

About the Institute for Advanced Medical Research

The mission of the Institute for Advanced Medical Research is to create a better world through the testing and ultimately the approval of new drugs to combat psychiatric and neurological disorders. Since 1998, it has been a leader in conducting clinical trials in the area of depression, anxiety, Alzheimer’s disease, PTSD and ADHD/ADD. Led by Dr. Angelo Sambunaris, Founder and Medical Director, and Dr. Prakash Masand, Chief Medical Officer, their team of experts are involved with all aspects of clinical research from diagnosis to progression to options for treatment. Learn more by visiting http://IAMResearch.org/.

Notes for editors

” A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended Release I Patients with Major Depressive Disorder” appears in the Journal of Clinical Psychopharmacology, Volume 34, Number1 (February 2014). http://www.psychopharmacology.com

Authors

Angelo Sambunars, M.D. Institute for Advanced Medical Research

Alpharetta, GA, USA

Additional Authors

Anjana Bose, Ph.D.

Carl P. Goimmoll, M.S.

Changzheng Chen. Ph.D.

William Greenberg, M.D.

David V. Sheehan, M.D., M.B.A.







Depression Drug Shows Promise for Future, Study Reports


Alpharetta, GA (PRWEB) November 25, 2014

The paper, “A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended Release In Patients with Major Depressive Disorder” was released in early 2014 and was the result of over one year of clinical research. Levomilnacipran, known as Fetzima ®, is a potent and selective serotonin and norepinephrine reuptake inhibitor that has been approved by the FDA for the treatment of depression. The research suggests that changes in symptom severity and improvement in functional impairment may occur asynchronously, with functional improvement often lagging behind symptoms. As such, symptom improvement may provide an early sign of treatment response, whereas functional improvement may be a better indicator of meaningful change according to a study published in the Journal of Clinical Psychopharmacology, Volume 34, Number 1, February 2014.

In this study conducted across a number of facilities that included Angelo Sambunaris, M.D., the research team performed trials to determine both efficacy (effectiveness) and tolerability (side effects) of the extended release (ER) formulation of this new medication.

“Studies like this one are an important step in the fight against depression,” said first author Dr. Sambunaris. Dr. Sambunaris is also the Founder and Medical Director of the Institute for Advanced Medical Research located in Alpharetta, GA. “We are always excited to share the results of our research studies with the medical community and patient group.”

About Angelo Sambunaris, M.D.

Dr. Angelo Sambunaris has been a leader in the field of clinical research for over two decades and currently serves as Founder, CEO and Medical Director of the Institute for Advanced Medical Research. He is also a clinical faculty member at the Mercer University School of Pharmacy. His experience helps him direct the clinical research team in conducting psychopharmacology (psychiatric medical care) and neuropharmacology (neurologic medical care) trials. The focus of his research is on Alzheimer’s disease and other dementias, anxiety disorders and depression, with additional interests in the areas of obsessive compulsive disorders, schizophrenia, stroke, insomnia, alcohol abuse/dependence, pain, migraine and obesity. As a veteran himself, he also has a particular interest in PTSD with soldiers.

Dr. Sambunaris earned his medical degree from the University of Colorado in Denver. Further studies continued with an internship in the Department of Medicine, Hershey Medical Center of the Pennsylvania State University; Psychiatry Residency, Department of Psychiatry, University of Colorado Health Sciences Center; Psychiatry Career Resident Program (externship), General Adult Psychiatric Services, Colorado State Hospital; and Clinical Staff Fellow, Neuropsychiatric Research Hospital National Institute of Mental Health, Washington, D.C.

In addition to his time in the Army and Colorado Army National Guard, he was also a member of the US Public Health Service and achieved the rank of Major with the Army and Lieutenant Commander in the PHS.

About the Institute for Advanced Medical Research

The mission of the Institute for Advanced Medical Research is to create a better world through the testing and ultimately the approval of new drugs to combat psychiatric and neurological disorders. Since 1998, it has been a leader in conducting clinical trials in the area of depression, anxiety, Alzheimer’s disease, PTSD and ADHD/ADD. Led by Dr. Angelo Sambunaris, Founder and Medical Director, and Dr. Prakash Masand, Chief Medical Officer, their team of experts are involved with all aspects of clinical research from diagnosis to progression to options for treatment. Learn more by visiting http://IAMResearch.org/.

Notes for editors

” A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended Release I Patients with Major Depressive Disorder” appears in the Journal of Clinical Psychopharmacology, Volume 34, Number1 (February 2014). http://www.psychopharmacology.com

Authors

Angelo Sambunars, M.D. Institute for Advanced Medical Research

Alpharetta, GA, USA

Additional Authors

Anjana Bose, Ph.D.

Carl P. Goimmoll, M.S.

Changzheng Chen. Ph.D.

William Greenberg, M.D.

David V. Sheehan, M.D., M.B.A.







Depression Drug Shows Promise for Future, Study Reports


Alpharetta, GA (PRWEB) November 25, 2014

The paper, “A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended Release In Patients with Major Depressive Disorder” was released in early 2014 and was the result of over one year of clinical research. Levomilnacipran, known as Fetzima ®, is a potent and selective serotonin and norepinephrine reuptake inhibitor that has been approved by the FDA for the treatment of depression. The research suggests that changes in symptom severity and improvement in functional impairment may occur asynchronously, with functional improvement often lagging behind symptoms. As such, symptom improvement may provide an early sign of treatment response, whereas functional improvement may be a better indicator of meaningful change according to a study published in the Journal of Clinical Psychopharmacology, Volume 34, Number 1, February 2014.

In this study conducted across a number of facilities that included Angelo Sambunaris, M.D., the research team performed trials to determine both efficacy (effectiveness) and tolerability (side effects) of the extended release (ER) formulation of this new medication.

“Studies like this one are an important step in the fight against depression,” said first author Dr. Sambunaris. Dr. Sambunaris is also the Founder and Medical Director of the Institute for Advanced Medical Research located in Alpharetta, GA. “We are always excited to share the results of our research studies with the medical community and patient group.”

About Angelo Sambunaris, M.D.

Dr. Angelo Sambunaris has been a leader in the field of clinical research for over two decades and currently serves as Founder, CEO and Medical Director of the Institute for Advanced Medical Research. He is also a clinical faculty member at the Mercer University School of Pharmacy. His experience helps him direct the clinical research team in conducting psychopharmacology (psychiatric medical care) and neuropharmacology (neurologic medical care) trials. The focus of his research is on Alzheimer’s disease and other dementias, anxiety disorders and depression, with additional interests in the areas of obsessive compulsive disorders, schizophrenia, stroke, insomnia, alcohol abuse/dependence, pain, migraine and obesity. As a veteran himself, he also has a particular interest in PTSD with soldiers.

Dr. Sambunaris earned his medical degree from the University of Colorado in Denver. Further studies continued with an internship in the Department of Medicine, Hershey Medical Center of the Pennsylvania State University; Psychiatry Residency, Department of Psychiatry, University of Colorado Health Sciences Center; Psychiatry Career Resident Program (externship), General Adult Psychiatric Services, Colorado State Hospital; and Clinical Staff Fellow, Neuropsychiatric Research Hospital National Institute of Mental Health, Washington, D.C.

In addition to his time in the Army and Colorado Army National Guard, he was also a member of the US Public Health Service and achieved the rank of Major with the Army and Lieutenant Commander in the PHS.

About the Institute for Advanced Medical Research

The mission of the Institute for Advanced Medical Research is to create a better world through the testing and ultimately the approval of new drugs to combat psychiatric and neurological disorders. Since 1998, it has been a leader in conducting clinical trials in the area of depression, anxiety, Alzheimer’s disease, PTSD and ADHD/ADD. Led by Dr. Angelo Sambunaris, Founder and Medical Director, and Dr. Prakash Masand, Chief Medical Officer, their team of experts are involved with all aspects of clinical research from diagnosis to progression to options for treatment. Learn more by visiting http://IAMResearch.org/.

Notes for editors

” A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended Release I Patients with Major Depressive Disorder” appears in the Journal of Clinical Psychopharmacology, Volume 34, Number1 (February 2014). http://www.psychopharmacology.com

Authors

Angelo Sambunars, M.D. Institute for Advanced Medical Research

Alpharetta, GA, USA

Additional Authors

Anjana Bose, Ph.D.

Carl P. Goimmoll, M.S.

Changzheng Chen. Ph.D.

William Greenberg, M.D.

David V. Sheehan, M.D., M.B.A.







Depression Drug Shows Promise for Future, Study Reports


Alpharetta, GA (PRWEB) November 25, 2014

The paper, “A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended Release In Patients with Major Depressive Disorder” was released in early 2014 and was the result of over one year of clinical research. Levomilnacipran, known as Fetzima ®, is a potent and selective serotonin and norepinephrine reuptake inhibitor that has been approved by the FDA for the treatment of depression. The research suggests that changes in symptom severity and improvement in functional impairment may occur asynchronously, with functional improvement often lagging behind symptoms. As such, symptom improvement may provide an early sign of treatment response, whereas functional improvement may be a better indicator of meaningful change according to a study published in the Journal of Clinical Psychopharmacology, Volume 34, Number 1, February 2014.

In this study conducted across a number of facilities that included Angelo Sambunaris, M.D., the research team performed trials to determine both efficacy (effectiveness) and tolerability (side effects) of the extended release (ER) formulation of this new medication.

“Studies like this one are an important step in the fight against depression,” said first author Dr. Sambunaris. Dr. Sambunaris is also the Founder and Medical Director of the Institute for Advanced Medical Research located in Alpharetta, GA. “We are always excited to share the results of our research studies with the medical community and patient group.”

About Angelo Sambunaris, M.D.

Dr. Angelo Sambunaris has been a leader in the field of clinical research for over two decades and currently serves as Founder, CEO and Medical Director of the Institute for Advanced Medical Research. He is also a clinical faculty member at the Mercer University School of Pharmacy. His experience helps him direct the clinical research team in conducting psychopharmacology (psychiatric medical care) and neuropharmacology (neurologic medical care) trials. The focus of his research is on Alzheimer’s disease and other dementias, anxiety disorders and depression, with additional interests in the areas of obsessive compulsive disorders, schizophrenia, stroke, insomnia, alcohol abuse/dependence, pain, migraine and obesity. As a veteran himself, he also has a particular interest in PTSD with soldiers.

Dr. Sambunaris earned his medical degree from the University of Colorado in Denver. Further studies continued with an internship in the Department of Medicine, Hershey Medical Center of the Pennsylvania State University; Psychiatry Residency, Department of Psychiatry, University of Colorado Health Sciences Center; Psychiatry Career Resident Program (externship), General Adult Psychiatric Services, Colorado State Hospital; and Clinical Staff Fellow, Neuropsychiatric Research Hospital National Institute of Mental Health, Washington, D.C.

In addition to his time in the Army and Colorado Army National Guard, he was also a member of the US Public Health Service and achieved the rank of Major with the Army and Lieutenant Commander in the PHS.

About the Institute for Advanced Medical Research

The mission of the Institute for Advanced Medical Research is to create a better world through the testing and ultimately the approval of new drugs to combat psychiatric and neurological disorders. Since 1998, it has been a leader in conducting clinical trials in the area of depression, anxiety, Alzheimer’s disease, PTSD and ADHD/ADD. Led by Dr. Angelo Sambunaris, Founder and Medical Director, and Dr. Prakash Masand, Chief Medical Officer, their team of experts are involved with all aspects of clinical research from diagnosis to progression to options for treatment. Learn more by visiting http://IAMResearch.org/.

Notes for editors

” A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended Release I Patients with Major Depressive Disorder” appears in the Journal of Clinical Psychopharmacology, Volume 34, Number1 (February 2014). http://www.psychopharmacology.com

Authors

Angelo Sambunars, M.D. Institute for Advanced Medical Research

Alpharetta, GA, USA

Additional Authors

Anjana Bose, Ph.D.

Carl P. Goimmoll, M.S.

Changzheng Chen. Ph.D.

William Greenberg, M.D.

David V. Sheehan, M.D., M.B.A.







Depression Drug Shows Promise for Future, Study Reports


Alpharetta, GA (PRWEB) November 25, 2014

The paper, “A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended Release In Patients with Major Depressive Disorder” was released in early 2014 and was the result of over one year of clinical research. Levomilnacipran, known as Fetzima ®, is a potent and selective serotonin and norepinephrine reuptake inhibitor that has been approved by the FDA for the treatment of depression. The research suggests that changes in symptom severity and improvement in functional impairment may occur asynchronously, with functional improvement often lagging behind symptoms. As such, symptom improvement may provide an early sign of treatment response, whereas functional improvement may be a better indicator of meaningful change according to a study published in the Journal of Clinical Psychopharmacology, Volume 34, Number 1, February 2014.

In this study conducted across a number of facilities that included Angelo Sambunaris, M.D., the research team performed trials to determine both efficacy (effectiveness) and tolerability (side effects) of the extended release (ER) formulation of this new medication.

“Studies like this one are an important step in the fight against depression,” said first author Dr. Sambunaris. Dr. Sambunaris is also the Founder and Medical Director of the Institute for Advanced Medical Research located in Alpharetta, GA. “We are always excited to share the results of our research studies with the medical community and patient group.”

About Angelo Sambunaris, M.D.

Dr. Angelo Sambunaris has been a leader in the field of clinical research for over two decades and currently serves as Founder, CEO and Medical Director of the Institute for Advanced Medical Research. He is also a clinical faculty member at the Mercer University School of Pharmacy. His experience helps him direct the clinical research team in conducting psychopharmacology (psychiatric medical care) and neuropharmacology (neurologic medical care) trials. The focus of his research is on Alzheimer’s disease and other dementias, anxiety disorders and depression, with additional interests in the areas of obsessive compulsive disorders, schizophrenia, stroke, insomnia, alcohol abuse/dependence, pain, migraine and obesity. As a veteran himself, he also has a particular interest in PTSD with soldiers.

Dr. Sambunaris earned his medical degree from the University of Colorado in Denver. Further studies continued with an internship in the Department of Medicine, Hershey Medical Center of the Pennsylvania State University; Psychiatry Residency, Department of Psychiatry, University of Colorado Health Sciences Center; Psychiatry Career Resident Program (externship), General Adult Psychiatric Services, Colorado State Hospital; and Clinical Staff Fellow, Neuropsychiatric Research Hospital National Institute of Mental Health, Washington, D.C.

In addition to his time in the Army and Colorado Army National Guard, he was also a member of the US Public Health Service and achieved the rank of Major with the Army and Lieutenant Commander in the PHS.

About the Institute for Advanced Medical Research

The mission of the Institute for Advanced Medical Research is to create a better world through the testing and ultimately the approval of new drugs to combat psychiatric and neurological disorders. Since 1998, it has been a leader in conducting clinical trials in the area of depression, anxiety, Alzheimer’s disease, PTSD and ADHD/ADD. Led by Dr. Angelo Sambunaris, Founder and Medical Director, and Dr. Prakash Masand, Chief Medical Officer, their team of experts are involved with all aspects of clinical research from diagnosis to progression to options for treatment. Learn more by visiting http://IAMResearch.org/.

Notes for editors

” A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended Release I Patients with Major Depressive Disorder” appears in the Journal of Clinical Psychopharmacology, Volume 34, Number1 (February 2014). http://www.psychopharmacology.com

Authors

Angelo Sambunars, M.D. Institute for Advanced Medical Research

Alpharetta, GA, USA

Additional Authors

Anjana Bose, Ph.D.

Carl P. Goimmoll, M.S.

Changzheng Chen. Ph.D.

William Greenberg, M.D.

David V. Sheehan, M.D., M.B.A.







Depression Drug Shows Promise for Future, Study Reports


Alpharetta, GA (PRWEB) November 25, 2014

The paper, “A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended Release In Patients with Major Depressive Disorder” was released in early 2014 and was the result of over one year of clinical research. Levomilnacipran, known as Fetzima ®, is a potent and selective serotonin and norepinephrine reuptake inhibitor that has been approved by the FDA for the treatment of depression. The research suggests that changes in symptom severity and improvement in functional impairment may occur asynchronously, with functional improvement often lagging behind symptoms. As such, symptom improvement may provide an early sign of treatment response, whereas functional improvement may be a better indicator of meaningful change according to a study published in the Journal of Clinical Psychopharmacology, Volume 34, Number 1, February 2014.

In this study conducted across a number of facilities that included Angelo Sambunaris, M.D., the research team performed trials to determine both efficacy (effectiveness) and tolerability (side effects) of the extended release (ER) formulation of this new medication.

“Studies like this one are an important step in the fight against depression,” said first author Dr. Sambunaris. Dr. Sambunaris is also the Founder and Medical Director of the Institute for Advanced Medical Research located in Alpharetta, GA. “We are always excited to share the results of our research studies with the medical community and patient group.”

About Angelo Sambunaris, M.D.

Dr. Angelo Sambunaris has been a leader in the field of clinical research for over two decades and currently serves as Founder, CEO and Medical Director of the Institute for Advanced Medical Research. He is also a clinical faculty member at the Mercer University School of Pharmacy. His experience helps him direct the clinical research team in conducting psychopharmacology (psychiatric medical care) and neuropharmacology (neurologic medical care) trials. The focus of his research is on Alzheimer’s disease and other dementias, anxiety disorders and depression, with additional interests in the areas of obsessive compulsive disorders, schizophrenia, stroke, insomnia, alcohol abuse/dependence, pain, migraine and obesity. As a veteran himself, he also has a particular interest in PTSD with soldiers.

Dr. Sambunaris earned his medical degree from the University of Colorado in Denver. Further studies continued with an internship in the Department of Medicine, Hershey Medical Center of the Pennsylvania State University; Psychiatry Residency, Department of Psychiatry, University of Colorado Health Sciences Center; Psychiatry Career Resident Program (externship), General Adult Psychiatric Services, Colorado State Hospital; and Clinical Staff Fellow, Neuropsychiatric Research Hospital National Institute of Mental Health, Washington, D.C.

In addition to his time in the Army and Colorado Army National Guard, he was also a member of the US Public Health Service and achieved the rank of Major with the Army and Lieutenant Commander in the PHS.

About the Institute for Advanced Medical Research

The mission of the Institute for Advanced Medical Research is to create a better world through the testing and ultimately the approval of new drugs to combat psychiatric and neurological disorders. Since 1998, it has been a leader in conducting clinical trials in the area of depression, anxiety, Alzheimer’s disease, PTSD and ADHD/ADD. Led by Dr. Angelo Sambunaris, Founder and Medical Director, and Dr. Prakash Masand, Chief Medical Officer, their team of experts are involved with all aspects of clinical research from diagnosis to progression to options for treatment. Learn more by visiting http://IAMResearch.org/.

Notes for editors

” A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended Release I Patients with Major Depressive Disorder” appears in the Journal of Clinical Psychopharmacology, Volume 34, Number1 (February 2014). http://www.psychopharmacology.com

Authors

Angelo Sambunars, M.D. Institute for Advanced Medical Research

Alpharetta, GA, USA

Additional Authors

Anjana Bose, Ph.D.

Carl P. Goimmoll, M.S.

Changzheng Chen. Ph.D.

William Greenberg, M.D.

David V. Sheehan, M.D., M.B.A.







Does a New Study Show at-Risk Brain Patterns for Alcoholism?

USA (PRWEB) November 20, 2014

Georgetown University are working on four major tests which could help develop concrete answers on what makes a teenager susceptible to alcoholism – even if they haven’t begun to drink yet, according to a Psych Central article dated November 16.

Their study focuses on a teenager’s brain while it is still being constructed, and aims to find patterns which suggest that a young person is prone to behaving riskily.

For now, they are drawing a contrast between the brains of teenagers who have gone on to abuse drugs and alcohol, as well as those who have not. So far, they have examined more than 100 boys who have an average age of 12 or 13. Their levels of impulsiveness, not to mention whether or not they prefer immediate reward or delayed gratification, were explored in detail.

A lot of the future does seem to hinge on a young boy’s emotions during his pre-adolescent years. Without actually looking at a person’s familial background, it can become easy to ascertain whether their anger, irritability or pessimistic look on life could contribute to their risk factor.

Other studies explored how well connected two key areas of the brain where – the insular cortex (which handles emotional responses) and the pre-frontal cortex. According to Georgetown academics, the weaker the link between these two regions, the more likely that the subject was an impulsive being who could turn to alcohol.

There was also a lot of scrutiny on sugar intake, as alcohol can form a considerable amount of a person’s calorific consumption over the course of a week or month. Existing research into alcoholics found that they have delectation for sweet products, and are more interested in immediate gratification.

The conclusions and experiences that can be drawn off this new study remains to be seen.

At Harbor Village, clients get a luxury drug addiction facility experience. During their stay, they experience hot, fresh meals, relaxing spa-like activities, Internet access, and the most excellent care. The medical staff at Harbor Village is well-trained, caring, and are there to help clients get through the painful and draining parts of their detox and withdrawal processes. Located in warm, sunny southern Florida, clients who seek help at Harbor Village will enjoy the peaceful and private setting of this luxury rehab. With private bedrooms, a great view, and more, Harbor Village aims to provide the most comfortable experience for anybody struggling with an addiction.

The mission statement of Harbor Village is to assist people from all walks of life with their addictions. For the last year, the peaceful and quiet environment of Harbor Village has helped make positive impacts in their lives. For the years to come, they hope to continue to help others see the light in their lives. Those who are looking for a safe, supervised, and peaceful detox process can get everything they are looking for and more at Harbor Village. Here, the goal is to help every client be happy, healthy, and ready to move on to the next step of his or her life.

For more information our luxury rehab center, or call the 24/7 hotline 1-855-290-4261.







Does a New Study Show at-Risk Brain Patterns for Alcoholism?

USA (PRWEB) November 20, 2014

Georgetown University are working on four major tests which could help develop concrete answers on what makes a teenager susceptible to alcoholism – even if they haven’t begun to drink yet, according to a Psych Central article dated November 16.

Their study focuses on a teenager’s brain while it is still being constructed, and aims to find patterns which suggest that a young person is prone to behaving riskily.

For now, they are drawing a contrast between the brains of teenagers who have gone on to abuse drugs and alcohol, as well as those who have not. So far, they have examined more than 100 boys who have an average age of 12 or 13. Their levels of impulsiveness, not to mention whether or not they prefer immediate reward or delayed gratification, were explored in detail.

A lot of the future does seem to hinge on a young boy’s emotions during his pre-adolescent years. Without actually looking at a person’s familial background, it can become easy to ascertain whether their anger, irritability or pessimistic look on life could contribute to their risk factor.

Other studies explored how well connected two key areas of the brain where – the insular cortex (which handles emotional responses) and the pre-frontal cortex. According to Georgetown academics, the weaker the link between these two regions, the more likely that the subject was an impulsive being who could turn to alcohol.

There was also a lot of scrutiny on sugar intake, as alcohol can form a considerable amount of a person’s calorific consumption over the course of a week or month. Existing research into alcoholics found that they have delectation for sweet products, and are more interested in immediate gratification.

The conclusions and experiences that can be drawn off this new study remains to be seen.

At Harbor Village, clients get a luxury drug addiction facility experience. During their stay, they experience hot, fresh meals, relaxing spa-like activities, Internet access, and the most excellent care. The medical staff at Harbor Village is well-trained, caring, and are there to help clients get through the painful and draining parts of their detox and withdrawal processes. Located in warm, sunny southern Florida, clients who seek help at Harbor Village will enjoy the peaceful and private setting of this luxury rehab. With private bedrooms, a great view, and more, Harbor Village aims to provide the most comfortable experience for anybody struggling with an addiction.

The mission statement of Harbor Village is to assist people from all walks of life with their addictions. For the last year, the peaceful and quiet environment of Harbor Village has helped make positive impacts in their lives. For the years to come, they hope to continue to help others see the light in their lives. Those who are looking for a safe, supervised, and peaceful detox process can get everything they are looking for and more at Harbor Village. Here, the goal is to help every client be happy, healthy, and ready to move on to the next step of his or her life.

For more information our luxury rehab center, or call the 24/7 hotline 1-855-290-4261.







Does a New Study Show at-Risk Brain Patterns for Alcoholism?

USA (PRWEB) November 20, 2014

Georgetown University are working on four major tests which could help develop concrete answers on what makes a teenager susceptible to alcoholism – even if they haven’t begun to drink yet, according to a Psych Central article dated November 16.

Their study focuses on a teenager’s brain while it is still being constructed, and aims to find patterns which suggest that a young person is prone to behaving riskily.

For now, they are drawing a contrast between the brains of teenagers who have gone on to abuse drugs and alcohol, as well as those who have not. So far, they have examined more than 100 boys who have an average age of 12 or 13. Their levels of impulsiveness, not to mention whether or not they prefer immediate reward or delayed gratification, were explored in detail.

A lot of the future does seem to hinge on a young boy’s emotions during his pre-adolescent years. Without actually looking at a person’s familial background, it can become easy to ascertain whether their anger, irritability or pessimistic look on life could contribute to their risk factor.

Other studies explored how well connected two key areas of the brain where – the insular cortex (which handles emotional responses) and the pre-frontal cortex. According to Georgetown academics, the weaker the link between these two regions, the more likely that the subject was an impulsive being who could turn to alcohol.

There was also a lot of scrutiny on sugar intake, as alcohol can form a considerable amount of a person’s calorific consumption over the course of a week or month. Existing research into alcoholics found that they have delectation for sweet products, and are more interested in immediate gratification.

The conclusions and experiences that can be drawn off this new study remains to be seen.

At Harbor Village, clients get a luxury drug addiction facility experience. During their stay, they experience hot, fresh meals, relaxing spa-like activities, Internet access, and the most excellent care. The medical staff at Harbor Village is well-trained, caring, and are there to help clients get through the painful and draining parts of their detox and withdrawal processes. Located in warm, sunny southern Florida, clients who seek help at Harbor Village will enjoy the peaceful and private setting of this luxury rehab. With private bedrooms, a great view, and more, Harbor Village aims to provide the most comfortable experience for anybody struggling with an addiction.

The mission statement of Harbor Village is to assist people from all walks of life with their addictions. For the last year, the peaceful and quiet environment of Harbor Village has helped make positive impacts in their lives. For the years to come, they hope to continue to help others see the light in their lives. Those who are looking for a safe, supervised, and peaceful detox process can get everything they are looking for and more at Harbor Village. Here, the goal is to help every client be happy, healthy, and ready to move on to the next step of his or her life.

For more information our luxury rehab center, or call the 24/7 hotline 1-855-290-4261.







Does a New Study Show at-Risk Brain Patterns for Alcoholism?

USA (PRWEB) November 20, 2014

Georgetown University are working on four major tests which could help develop concrete answers on what makes a teenager susceptible to alcoholism – even if they haven’t begun to drink yet, according to a Psych Central article dated November 16.

Their study focuses on a teenager’s brain while it is still being constructed, and aims to find patterns which suggest that a young person is prone to behaving riskily.

For now, they are drawing a contrast between the brains of teenagers who have gone on to abuse drugs and alcohol, as well as those who have not. So far, they have examined more than 100 boys who have an average age of 12 or 13. Their levels of impulsiveness, not to mention whether or not they prefer immediate reward or delayed gratification, were explored in detail.

A lot of the future does seem to hinge on a young boy’s emotions during his pre-adolescent years. Without actually looking at a person’s familial background, it can become easy to ascertain whether their anger, irritability or pessimistic look on life could contribute to their risk factor.

Other studies explored how well connected two key areas of the brain where – the insular cortex (which handles emotional responses) and the pre-frontal cortex. According to Georgetown academics, the weaker the link between these two regions, the more likely that the subject was an impulsive being who could turn to alcohol.

There was also a lot of scrutiny on sugar intake, as alcohol can form a considerable amount of a person’s calorific consumption over the course of a week or month. Existing research into alcoholics found that they have delectation for sweet products, and are more interested in immediate gratification.

The conclusions and experiences that can be drawn off this new study remains to be seen.

At Harbor Village, clients get a luxury drug addiction facility experience. During their stay, they experience hot, fresh meals, relaxing spa-like activities, Internet access, and the most excellent care. The medical staff at Harbor Village is well-trained, caring, and are there to help clients get through the painful and draining parts of their detox and withdrawal processes. Located in warm, sunny southern Florida, clients who seek help at Harbor Village will enjoy the peaceful and private setting of this luxury rehab. With private bedrooms, a great view, and more, Harbor Village aims to provide the most comfortable experience for anybody struggling with an addiction.

The mission statement of Harbor Village is to assist people from all walks of life with their addictions. For the last year, the peaceful and quiet environment of Harbor Village has helped make positive impacts in their lives. For the years to come, they hope to continue to help others see the light in their lives. Those who are looking for a safe, supervised, and peaceful detox process can get everything they are looking for and more at Harbor Village. Here, the goal is to help every client be happy, healthy, and ready to move on to the next step of his or her life.

For more information our luxury rehab center, or call the 24/7 hotline 1-855-290-4261.